![](https://etira.life/wp-content/uploads/2023/06/nature-cancer-thumbnail-495x400.jpg)
Breakthroughs that
See what others are saying about Etira and our innovations
![](https://etira.life/wp-content/uploads/2023/06/nature-cancer-thumbnail-495x400.jpg)
![](https://etira.life/wp-content/uploads/2023/04/Annual-Meet-Feature-Image-495x400.jpg)
Positive preclinical data presented at AACR 2023
News Dallas, Texas. April 18, 2023:
Etira is pleased to announce that multiple abstracts related to their licensed products showed encouraging preclinical activity in metastatic breast cancer and ovarian cancer. The data, presented…
![](https://etira.life/wp-content/uploads/2023/04/UT-Health-Feature-Health-495x400.jpg)
Etira founder Dr. Ratna Vadlamudi honored with the prestigious 2023 Distinguished Research Scholar Award
NewsDallas, Texas. April 17, 2023:We are excited to congratulate one of our founders, Dr. Ratna Vadlamudi, Professor and Vice Chair for Research, Division of Reproductive Research, Department of Obstetrics & Gynecology, Long School of…
![](https://etira.life/wp-content/uploads/2022/12/San-Antonio-Breast-Cancer-Thumbnail-1-495x400.jpg)
Preclinical data on TNBC presented at SABCS 2022
NewsDallas, Texas. December 9, 2022:
Etira is pleased to report the abstract related to ERX-41 validating its activity in Triple negative breast cancer was presented at the San Antonio Breast Cancer Symposium (SABCS). The SABCS is one of the world's…
![](https://etira.life/wp-content/uploads/2022/10/Annual-Meet-Feature-Image-495x400.jpg)
Etira founder Dr. Jung-Mo Ahn highlighted in local press
NewsDallas, Texas. October 31, 2022. We are pleased to share two news articles from Dallas that describe how our brilliant chemist and founder, Dr. Jung-Mo Ahn discovered ERX-41. In his words, Dr. Ahn describes the discovery of ERX-41 as “It’s…
![](https://etira.life/wp-content/uploads/2022/10/Oncology-thumbnail-495x400.jpg)
Oncology Times Highlights ERX-41
NewsDallas, Texas. October 10, 2022:etiraRx's lead drug candidate, ERX-41 has been highlighted in the most recent edition of Oncology Times. In an article entitled "Molecule Targets Vulnerability in Triple-Negative Breast Cancer," Dibash Kumar…
Where to find us
Boston Office:
75 Kneeland Ave, 14th Floor
Boston. MA. 02111
Dallas Office:
3033 Irving Blvd,
Dallas. TX. 75247